Jubilant Pharmova Limited · NSE:JUBLPHARMA

Jubilant Pharmova — Jubilant Life Sciences — Q3 FY2017 Earnings Presentation

23 slides from Jubilant Pharmova's earnings presentation, Feb 7, 2017

  1. Slide 1: Financial Results Quarter Ended December 31, 2016

    Financial Results Quarter Ended December 31, 2016

  2. Slide 2: Disclaimer

    Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f

  3. Slide 3: Conference Call Details

    Conference Call Details Date : Tuesday, February 07, 2017 Time : 05:00 pm IST Primary Number: +91 22 3938 1071 3940 3977 Available in ‐ Ahmedabad, Bengaluru, Chandigarh, Chennai, Local Access Number: Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Pune, Lucknow. Accessible from all carriers. USA: 1 866 7

  4. Slide 4: Q3'17 Results Analysis

    eae ZZ PG JUBHANT LIFESCIENCES Q3’17 Results Analysis

  5. Slide 5: Income Statement – Q3'FY17

    Income Statement – Q3’FY17 Particulars Q3'FY16 Q3'FY17 YoY Growth (Rs Crs) (%) Total Income from Operations 1,401 1,492 7% Pharmaceuticals 684 785 15% Life Science Ingredients 683 663 ‐3% Drug Discovery Solutions 34 44 28% Total Expenditure 1,095 1,160 6% Other Income 3 5 80% EBITDA including Other

  6. Slide 6: Financial Highlights – Q3'FY17

    Financial Highlights – Q3’FY17 • Consolidated revenue at Rs. 1,492 Crore; up 7% YoY • Pharmaceuticals revenue at Rs. 785 Crore, contributing 53% to the revenues, up 15% YoY • Life Science Ingredients revenue at Rs. 663 Crore, down 3% YoY and up 8% QoQ • Drug Discovery Solutions revenue at Rs. 44 Cro

  7. Slide 7: Pharma Business Highlights – Q3'FY17

    Pharma Business Highlights – Q3’FY17 • Revenues of Rs. 785 Crore, up 15% YoY • Specialty Pharmaceuticals (Sterile Products) revenues reported robust growth of 26% YoY; contributing 56% to segment sales • Generics revenues grew 3% YoY, led by growth in APIs business • Successfully completed USFDA ins

  8. Slide 8: Pharma Business Highlights – Q3'FY17

    Pharma Business Highlights – Q3’FY17 Region‐wise Revenue (Rs crs) Q3'FY16 Q2'FY17 Q3'FY17 Mix % YoY % QoQ % International 644 706 745 95% 16% 6% North America 484 527 529 67% 9% 0% Europe & Japan 94 93 138 18% 47% 49% ROW 67 86 79 10% 17% ‐8% India 40 63 39 5% 0% ‐37% Income from Operations 684 769

  9. Slide 9: LSI Business Highlights – Q3'FY17

    LSI Business Highlights – Q3’FY17 Region‐wise Revenue (Rs crs) Q3'FY16 Q2'FY17 Q3'FY17 Mix % YoY % QoQ % International 329 241 273 41% ‐17% 13% Europe, North America and Japan 230 174 192 29% ‐17% 10% China and ROW 99 67 81 12% ‐18% 22% India 354 371 390 59% 10% 5% Income from Operations 683 613 663

  10. Slide 10: Drug Discovery Solutions Business Highlights – Q3'FY17

    Drug Discovery Solutions Business Highlights – Q3’FY17 • Revenues at Rs. 44 Crore, grew 28% YoY; Contributes 3% to total revenues • EBITDA at Rs. 6 Crore, EBITDA margins at 13.3%, up from 1.3% in Q3’16 • In Proprietary Drug Discovery, the pipeline of novel products continues to remain very strong. W

  11. Slide 11: Nine-Monthly Results Analysis

    Nine‐Monthly Results Analysis 10 10

  12. Slide 12: Income Statement – 9M'FY17

    Income Statement – 9M’FY17 Particulars 9M'FY16 9M'FY17 YoY Growth (Rs Crs) (%) Total Income from Operations 4,377 4,365 0% Pharmaceuticals 2,100 2,308 10% Life Science Ingredients 2,191 1,926 ‐12% Drug Discovery Solutions 86 131 53% Total Expenditure 3,423 3,325 ‐3% Other Income 11 14 29% EBITDA inc

  13. Slide 13: Financial Highlights – 9M'FY17

    Financial Highlights – 9M’FY17 • Consolidated revenue at Rs. 4,365 Crore • Pharmaceuticals revenue at Rs. 2,308 Crore, up 10% YoY, contributing 53% to the revenues • LSI revenue at Rs. 1,926 Crore, contributing 44% to the revenues • Drug Discovery Solutions revenue at Rs. 131 Crore, up 53% YoY, cont

  14. Slide 14: Pharma Business Highlights – 9M'FY17

    Pharma Business Highlights – 9M’FY17 • Revenues of Rs. 2,308 Crores, up 10% YoY • Specialty Pharmaceuticals (Sterile Products) revenues grow 11% YoY; contribute 53% to segment sales • Generics revenues grew 9% YoY, led by strong growth in APIs business • USFDA inspections of Roorkee, Radiopharmaceut

  15. Slide 15: Pharma Business Highlights – 9M'FY17

    Pharma Business Highlights – 9M’FY17 Geo‐wise Revenue (Rs crs) 9M'FY16 9M'FY17 Mix % YoY % International 1,985 2,156 93% 9% USA & Canada 1,547 1,570 68% 1% Europe & Japan 263 336 15% 28% ROW 175 250 11% 43% India 115 152 7% 32% Income from Operations 2,100 2,308 100% 10%  International Revenues gro

  16. Slide 16: Portfolio of R&D products – Filings and Approvals

    Portfolio of R&D products – Filings and Approvals Product pipeline as on December 31, 2016 Dosage (Orals) Sterile including JDI Region Total Filings Approval Pending Total Filings Approval Pending US 73 49 24 12 9 3 Canada 22 19 3 14 14 0 Europe 99 96 3 12 11 1 ROW 618 458 160 44 40 4 Total 812 622

  17. Slide 17: Filings and Approvals

    Filings and Approvals Dosage (Orals)  Filed 73 ANDAs in the US i. 49 ANDAs have been approved and 24 ANDAs are pending approval ii. We plan to file about 8 ANDAs in FY 17  Made 739 filings in ROW markets including Canada, Europe and Japan i. 573 filings have been approved and 166 filings are pendi

  18. Slide 18: Portfolio of Radiopharmaceuticals Sterile Products – Filings and Approvals

    Portfolio of Radiopharmaceuticals Sterile Products – Filings and Approvals  Orphan Drug I‐131 MIBG – potential NDA filing in US i. Jubilant has received Orphan drug status with eligibility for accelerated approval ii. Indicated for paediatric Neuroblastoma, accounting for 6‐10% of cancers in childr

  19. Slide 19: LSI Business Highlights – 9M'FY17

    LSI Business Highlights – 9M’FY17 Geo‐wise Revenue (Rs crs) 9M'FY16 9M'FY17 Mix % YoY % International 1,025 810 42% ‐21% Europe, North America and Japan 687 575 30% ‐16% China and ROW 338 235 12% ‐30% India 1,167 1,115 58% ‐4% Income from Operations 2,191 1,926 100% ‐12% • Revenues at Rs. 1,926 Cror

  20. Slide 20: Drug Discovery Solutions Business Highlights – 9M'FY17

    Drug Discovery Solutions Business Highlights – 9M’FY17 • Revenues at Rs. 131 Crore, grow 53% YoY; Contributes 3% to total revenues • EBITDA at Rs. 20 Crore, including out‐licensing income of US$ 2 Million, up from Rs. (2) Crore in 9M’16 • Proprietary Drug Discovery  Out‐licensing of family of paten

  21. Slide 21: Debt Profile

    Debt Profile Particulars 31‐Mar‐16 30‐Sep‐16 31‐Dec‐16 Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) Standalone 55 35 19 Subsidiaries 320 267 403 Total 375 302 422 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 1,422 1,485 1,253 Subsidiaries 626 624 41 Total 2,047 2,109 1,294 Gross Debt 4,534 4,

  22. Slide 22: Outlook

    Outlook  The revenue and profitability is expected to be robust, led by better revenue quality in our Specialty Pharmaceuticals (Sterile Products) business. Going forward, the growth will be driven by: • In Pharmaceuticals segment: • Specialty Pharmaceuticals (Sterile Products): Growth in Radiophar

  23. Slide 23: For more information

    For more information For Investors: Ravi Agrawal Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91‐120‐436 1002 Ph: +91‐22‐6645 1209 E‐mail: ravi_agrawal@jubl.com E‐mail: siddharth@cdr‐india.com For Media: Sudhakar Safaya Kanika Bansal Jubilant Life Sciences Limited Perfect Relati

Jubilant Life Sciences — Q3 FY2017 Earnings Presentation on 6ix